Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with Prof. Dr. Günter Höglinger, Director of the Department of Neurology at LMU Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany, to discuss the treatment landscape for people living with progressive supranuclear palsy (PSP) and the Company’s clinical development plans for AMX0035 in PSP on July 26, 2023 at 1:30pm ET.
- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with Prof. Dr. Günter Höglinger, Director of the Department of Neurology at LMU Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany, to discuss the treatment landscape for people living with progressive supranuclear palsy (PSP) and the Company’s clinical development plans for AMX0035 in PSP on July 26, 2023 at 1:30pm ET.
- Prof. Dr. Höglinger studied medicine and physics at the universities of Regensburg and Würzburg and earned his PhD in medicine, summa cum laude, in 2000.
- Since 2011, he has held the Chair of the Department of Translational Neurodegeneration at the German Center for Neurodegenerative Diseases, DZNE.
- For many years, Prof. Dr. Höglinger has been conducting translational research into tauopathies and was actively involved in many international clinical trials in PSP.